Hoth Therapeutics Inc announces that it has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, patented antimicrobial therapy focused on treating atopic dermatitis.
This agreement serves as an extension to the previously executed sublicense agreement for the compound with Chelexa Biosciences Inc, the company notes in a media release.
According to the National Eczema Association, “Atopic dermatitis (also known as AD) is the most common type of eczema. In fact, more than 18 million American adults have atopic dermatitis — which often appears as a red, itchy rash normally on the cheeks, arms and legs. Atopic dermatitis typically begins in childhood, usually in the first six months of a baby’s life. Even though it’s a common form of eczema, it’s also severe and long-lasting. When you or your child have atopic dermatitis, it may improve at times, but at others it may get worse. Often, atopic dermatitis disappears as a child grows older, though some children will have atopic dermatitis flares into adulthood.”
Atopic dermatitis exists with two other allergic conditions: asthma and hay fever (allergic rhinitis). People who have asthma and/or hay fever or who have family members who do, are more likely to develop AD, per the release.
“Management is pleased to fully own global licensing rights for the BioLexa Platform,” says Robb Knie, CEO of Hoth Therapeutics.
[Source(s): Hoth Therapeutics Inc, PR Newswire]
